DSP-107

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameDSP-107
Drug Alias NameDSP-107KAHR-107
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitorsAnti-Tumor necrosis factor receptor superfamily member 9
TargetsCluster of differentiation 47Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKahr Medical
China Registration ClassN/A

Develop Information

Active CompaniesKahr Bio Australia Pty LtdKahr Medical
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A